Your primary care team at Hopkins MD is here to break it down for you
If our cells are not healthy, we may not be optimally healthy
When he previewed these results last month, he said this product is shaping up according to plans: The goal was to create an oral pill that was convenient and can be made at a huge scale, really, for the mass market, and had weight loss that was competitive with other single-acting GLP-1s, and thats what weve achieved. Sean Wharton, lead author on the NEJM publication, expresses hope for reaching many more people with this medicine: This could mean an expansion of obesity interventions to groups who are currently excluded due to the cost of and lack of access to injectable medications. One in Five Lost 20% or More The ATTAIN-1 trial of this first-in-class, oral, small-molecule GLP-1 receptor agonist enrolled 3,127 adults with obesity but not diabetes
Take your medication at regular intervals
This prevents degradation and contamination
About this article Cite this article Lin, A., Ding, Y., Li, Z